- Home
- OPFI vs ABEO Comparison
OPFI vs ABEO Comparison
Compare OPFI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- ABEO
- Stock Information
- Founded
- OPFI 2009
- ABEO 1974
- Country
- OPFI United States
- ABEO United States
- Employees
- OPFI N/A
- ABEO N/A
- Industry
- OPFI Finance: Consumer Services
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- ABEO Health Care
- Exchange
- OPFI Nasdaq
- ABEO Nasdaq
- Market Cap
- OPFI 300.3M
- ABEO 332.0M
- IPO Year
- OPFI N/A
- ABEO 1980
- Fundamental
- Price
- OPFI $10.17
- ABEO $6.83
- Analyst Decision
- OPFI Buy
- ABEO Strong Buy
- Analyst Count
- OPFI 2
- ABEO 6
- Target Price
- OPFI $11.75
- ABEO $18.17
- AVG Volume (30 Days)
- OPFI 1.3M
- ABEO 702.3K
- Earning Date
- OPFI 08-06-2025
- ABEO 08-14-2025
- Dividend Yield
- OPFI 9.79%
- ABEO N/A
- EPS Growth
- OPFI N/A
- ABEO N/A
- EPS
- OPFI N/A
- ABEO 0.99
- Revenue
- OPFI $320,831,000.00
- ABEO $400,000.00
- Revenue This Year
- OPFI $116.69
- ABEO N/A
- Revenue Next Year
- OPFI $9.90
- ABEO $339.63
- P/E Ratio
- OPFI N/A
- ABEO $6.91
- Revenue Growth
- OPFI 31.26
- ABEO N/A
- 52 Week Low
- OPFI $3.93
- ABEO $3.93
- 52 Week High
- OPFI $17.73
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- OPFI 46.36
- ABEO 52.71
- Support Level
- OPFI $10.11
- ABEO $6.70
- Resistance Level
- OPFI $10.76
- ABEO $7.15
- Average True Range (ATR)
- OPFI 0.47
- ABEO 0.31
- MACD
- OPFI 0.08
- ABEO -0.02
- Stochastic Oscillator
- OPFI 51.49
- ABEO 46.62
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.